INTRODUCTION
============

Regenerative medicine provides a valuable therapeutic framework for remedying remedy difficult-to-treat diseases and impaired tissue. The term "regenerative medicine" was first used by Kaiser in 1992 \[[@b1-inj-2040150-075]\]. Cell-based therapy and tissue engineering are the two most significant components of regenerative medicine, and each of them can be applied independently or in combination to generate synergistic effects \[[@b2-inj-2040150-075]\]. In the history of regenerative medicine in urology, Atala et al. \[[@b3-inj-2040150-075],[@b4-inj-2040150-075]\] showed promising results by implanting a tissue-engineered bladder and urethra using autologous cells and scaffolds in humans for the first time. Since then, extensive research has investigated the possibility of using stem cells for therapeutic purposes in various difficult-to-treat urologic diseases such as incontinence, neurogenic bladder (NB), erectile dysfunction, and interstitial cystitis/bladder pain syndrome \[[@b5-inj-2040150-075]\].

Stem cell therapy has been invaluable in the treatment of numerous serious diseases that cannot be adequately treated with existing therapeutic modalities. Therefore, NB associated with central nervous injury or dysfunction is an optimal candidate for stem cell therapy because it is challenging to promote the recovery of injuries or degenerative changes in the central nervous system \[[@b6-inj-2040150-075]-[@b8-inj-2040150-075]\]. Disability induced by spinal cord injury (SCI) is a serious problem that impacts quality of life, and its prevalence is noteworthy, although the exact incidence has not been determined. In aging societies, falls are common among elderly individuals, which has contributed to an increasing incidence of SCI \[[@b9-inj-2040150-075],[@b10-inj-2040150-075]\]. One of the most common problems in SCI patients is NB; however, the current medical and surgical treatment of NB focuses only on modulating the function of the bladder, not on promoting recovery of the SCI \[[@b11-inj-2040150-075],[@b12-inj-2040150-075]\]. In addition, the therapeutic outcome of NB treatment is generally insufficient because the SCI is often permanent. Thus, neuronal regeneration using stem cell therapy may contribute to the restoration of functional impairment after SCI.

MECHANISM OF STEM CELL THERAPY IN NEURAL REGENERATION AFTER SPINAL CORD INJURY
==============================================================================

At present, the Wnt/β-catenin signaling pathway, the Rho/Rock signaling pathway, the Notch signaling pathway, and the JAK-STAT3 signaling pathway have been considered as possible signaling pathways associated with neural regeneration after stem cell therapy. After SCI activation of the Wnt/β-catenin signaling pathway promotes neural regeneration, while the Rho/Rock signaling pathway, the Notch signaling pathway, and the JAK-STAT3 signaling pathway inhibit neural regeneration. The Wnt/β-catenin signaling pathway contributes to the development of the nervous system and is activated in the early period after SCI and subsequently decreases with time. Wnt expression increases rapidly in the acute phase of SCI. Therefore, increased expression of Wnt plays a role in recruiting endogenous neural stem cells and in restoring damaged neural tissue \[[@b13-inj-2040150-075]-[@b20-inj-2040150-075]\]. Thus, up- or down-regulation of these signaling pathways influences the neural differentiation of stem cells.

To improve the role of stem cells in repairing damaged tissue, the microenvironmental balance around stem cells is also important. The extracellular matrix (ECM), cytokines, and tissue-specific cells modulate the microenvironment, and an imbalance of these components inhibits neural regeneration. The ECM is a 3-dimensional network that shapes the central nervous system, and breakdown of the ECM after SCI influences neuronal and nonneuronal cell migration, communication, and survival, which are important for recovery from SCI. Therefore, ensuring an adequate ECM for the damaged spinal cord is a therapeutic approach that aims to provide a proper environment for repair after SCI \[[@b21-inj-2040150-075]\]. Several studies have shown a synergistic effect after combined treatment with biocompatible scaffolds and stem cells \[[@b22-inj-2040150-075]-[@b24-inj-2040150-075]\]. Moreover, the paracrine effect of stem cells promotes neural regeneration by regulating neurotrophic factors, cytokines, and chemokines \[[@b25-inj-2040150-075]\].

PRECLINICAL STEM CELL THERAPY FOR THE TREATMENT OF SPINAL CORD INJURY
=====================================================================

Multiple preclinical studies have investigated the use of various types of stem cells after SCI, evaluating the roles of mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural stem cells in morphological and functional recovery after SCI. Many studies have investigated stem cell therapy with MSC have been performed because MSCs because MSCs have considerable potential for differentiation and anti-inflammatory and immunomodulatory properties \[[@b26-inj-2040150-075]\]. MSCs can be isolated from various tissues, such as the bone marrow, umbilical cord, adipose tissue, and oral mucosa. All types of MSCs have been shown to lead to neural regeneration in a SCI animal model induced by spinal cord transection and contusion. Moreover, therapeutic effects of MSCs have been observed in both the acute and chronic phases after SCI. Regarding the route of administration, direct injection to the injured area and intravenous or intrathecal administration of MSCs have led to improved neural regeneration \[[@b27-inj-2040150-075]-[@b32-inj-2040150-075]\]. Bone marrow mesenchymal stem cells (BM-MSC) is low immunogenicity compared with MSCs from other tissue. However, considerable pain that occurs during the process of obtaining BM-MSC from bone marrow is an issue. In contrast, adipose-derived stem cells (ADSCs) have the advantage of being readily obtainable from adipose tissue. Therefore, the patient experiences less pain than when BM-MSCs are used.

Many studies have investigated the use of iPSCs because iPSCs derived from autologous somatic cells have similar characteristics to embryonic stem cells, therevy circumventing ethical issues \[[@b33-inj-2040150-075]\]. Several studies have shown autologous iPSC-derived neural precursor cells exerted effects on neural regeneration through remyelination after SCI \[[@b34-inj-2040150-075]-[@b36-inj-2040150-075]\]. However, iPSCs have a higher rate of tumorigenicity due to the epigenetic memory of the original somatic cells and reprogramming. Neural stem cells are obtained from the brain (lateral ventricle, dentate gyrus of the hippocampus) and the central canal of the spinal cord. Neural stem cells can differentiate into neurons, astrocytes, and oligodendrocytes in the nervous system \[[@b37-inj-2040150-075]\]. Previous studies of neural stem cells showed axonal regeneration at the injured area and functional recovery \[[@b38-inj-2040150-075]\].

CLINICAL TRIALS OF STEM CELL THERAPY AFTER SPINAL CORD INJURY
=============================================================

A considerable number of clinical trials that have evaluated the effects and safety of stem cell therapy in SCI patients on the basis of preclinical research. Therefore, a review of clinical trials registered on ClinicalTrials.gov was performed to evaluate the outcomes of stem cell therapy in SCI patients. In total, 30 clinical trials were identified (complete: n=18 and ongoing: n=12), excluding withdrawn and terminated studies. Six of the 18 completed studies reported the results of the trials ([Table 1](#t1-inj-2040150-075){ref-type="table"}). The completed clinical trials were phase 1 or 2 studies, and types of stem cells were autologous BM-MSCs, autologous ADSCs, and umbilical cord mesenchymal stem cells (UC-MSCs) \[[@b39-inj-2040150-075]-[@b43-inj-2040150-075]\]. There was only one phase 3 clinical trial, which compared a stem cell transplantation group, a rehabilitation group, and a blank control group \[[@b43-inj-2040150-075]\]. The route of administration was injection the injured area, intrathecal injection, and intravenous infusion. Three studies performed stem cell therapy together with other treatments, such as decompression of the spinal lesion; physiotherapy involving mat activities, strengthening exercises, self-range of motion, ambulation training for paraplegic patients, and cardiopulmonary training; and rehabilitation therapy \[[@b39-inj-2040150-075],[@b41-inj-2040150-075],[@b43-inj-2040150-075]\].

The baseline severity of SCI was classified according to the American Spinal Injury Association (ASIA) impairment score. After stem cell treatment, sensory and motor function was evaluated with the ASIA impairment score, the Association Impairment Scale score, and somatosensory evoked potentials. Some studies used computed tomography and magnetic resonance imaging of the spinal cord to assess structural changes after stem cell treatment. The 6 studies that reported results showed improvements in sensory and motor function, regardless of the types of stem cells and administration route. A combination of stem cell therapy with physiotherapy and rehabilitation therapy showed remarkable improvements in motor function compared with the patients treated with physiotherapy and rehabilitation therapy only. In addition, no severe adverse events were observed in any studies, and only mild and transient adverse events such as headache, low-level pain, and nonspecific tingling sensations were reported.

PRECLINICAL STEM CELL THERAPY FOR THE TREATMENT OF NEUROGENIC BLADDER AFTER SPINAL CORD INJURY
==============================================================================================

NB is a commonly observed functional impairment after SCI, and several animal studies have evaluated the effects of stem cell therapy on bladder function. Previous studies used various SCI animal models to represent NB in SCI patients, and SCI was induced by contusion, transection, and needle-stick injury of the spinal cord \[[@b44-inj-2040150-075]-[@b50-inj-2040150-075]\]. Five different sources were used: BM-MSCs, human UC-MSCs, neuronal stem cells, human MSCs, and oral mucosa stem cells. Most of the studies administered stem cells through direct injection to the injured area between 3 days and 13 weeks after the injury. Bladder function was evaluated by performing a urodynamic study (UDS) after stem cell therapy. Compared with the SCI group without treatment, the stem cell therapy group showed decreased voiding pressure and non-voiding contraction and increased bladder compliance and bladder capacity. In addition to UDS, some previous studies simultaneously evaluated sensory and motor function. Functional changes after stem cell therapy varied from minimal to a significant improvement.

CLINICAL TRIALS OF STEM CELL THERAPY FOR NEUROGENIC BLADDER AFTER SPINAL CORD INJURY
====================================================================================

There were 10 clinical trials of stem cell therapy for NB after SCI that included evaluations of bladder function. Among them, 5 studies were completed, and 5 studies were ongoing ([Table 2](#t2-inj-2040150-075){ref-type="table"}). All of them except 1 study (phase 3) \[[@b43-inj-2040150-075]\] were phase 1 or 2 clinical trials, and they used stem cells such as autologous BM-MSCs, UC-MSCs, Wharton's jelly MSCs, and human-spinal cord-derived neural stem cells. The administration route in most of these studies was intrathecal injection. In 1 study (NCT01909154; see [Table 1](#t1-inj-2040150-075){ref-type="table"}), a second injection was performed 3 months after the first injection. Bladder function was evaluated with UDS in the completed clinical trials except for 1 study (NCT02570932). Increased maximum cytometric capacity, improved compliance, and decreased detrusor pressure were noted, with results comparable to those of preclinical studies. However, these improvements of UDS did not reduce urinary incontinence or eliminate the need for clean intermittent catheterization (CIC). Five ongoing clinical trials are planning to evaluate bladder function with UDS, measurements of postvoid residual urine volume, and data obtained via questionnaires.

WHAT IS NECESSARY FOR CLINICAL APPLICATIONS?
============================================

Increasingly many preclinical and clinical studies have investigated the effects of stem cell therapy on NB related to SCI, and several positive results have been reported in previous clinical trials. However, many questions remain about the effects and safety of stem cell therapy. Most of the previous clinical trials were not randomized trials, did not have a control group, and included a small number of patients. Moreover, the dose, route of administration, and timing were different in each of the studies. Furthermore, no studies demonstrated functional recovery of voiding; as mentioned above, patients still had persistent urinary incontinence and a continuing need for CIC. Furthermore, no study showed improvements in sensory and motor function after stem cell therapy. Therefore, further studies are necessary to demonstrate clear evidence regarding stem cell therapy and the appropriate direction for standardization of therapeutic methods. Moreover, the Tissue Engineering & Regenerative Medicine International Society (TERMIS) suggested 5 significant drivers for the translation of regenerative medicine, including stem cell therapy, to real clinical practice \[[@b51-inj-2040150-075]\]. The major drivers pointed out by TERMIS are: fully validated manufacturing capability for stem cells, reimbursement for NB related to SCI, regulation of the design and development of stem cells that will show consistent effect and safety, collaboration among various researchers and economic actors, and clinical development plans to reduce the risk of failure.

CONCLUSIONS
===========

Stem cell therapy is a promising therapeutic option for NB related to SCI, and many preclinical and clinical studies have been conducted to demonstrate the efficacy and safety of stem cell therapy. Several clinical trials have demonstrated improvements in bladder function. However, clear evidence is lacking because most of the extant clinical trials were not high-quality, and therapeutic methods varied among the studies. Therefore, there is a pressing need for further studies to demonstrate evidence of the therapeutic potential of stem cell therapy and to enable the translation of stem cell therapy to real-world practice.
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###### 

Completed clinical trials that reported results (<http://clinicaltrials.gov/>)

  Identifier                               Clinical trial phase   Type of SCI                                       No. of patients   Age (yr), range   Cell type                                                                                                     Delivery method                                                                         Efficacy                                                                                                                                                                                              Safety
  ---------------------------------------- ---------------------- ------------------------------------------------- ----------------- ----------------- ------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  NCT01325103 \[[@b39-inj-2040150-075]\]   Phase 1                Thoracic or lumbar traumatic SCI (ASIA grade A)   14                18--65            Autologous BM-MSC                                                                                             Intralesional injection after laminectomy and decompression of the spinal lesion area   Variably enhanced sensitivity below the injury area was observed. 8 patients: improvement of lower limb motor function, 7 patients: improvement of AIS, 3 patients: improvement of neuropathic pain   14 Patients: discharge within 48 hours after surgery, 1: cerebrospinal leak related to surgery, no severe adverse events
  NCT02482194 \[[@b40-inj-2040150-075]\]   Phase 1                Chronic and subacute SCI                          9                 18--50            Autologous BM-MSCs                                                                                            Intrathecal injection                                                                   At 1 year after treatment, no alteration in the hyperintense signal and no formation of ectopic tissue                                                                                                No severe adverse event, 1 patient: severe headache, 2 patients: nonspecific tingling sensation
  NCT01909154                              Phase 1                Chronic paraplegia (ASIA grade A)                 9                 18--50            Autologous BM-MSCs                                                                                            Intrathecal injection (second injection at 3 months after the first injection)          Sensory recovery, improvement of chronic pain, presence of SSEPs                                                                                                                                      No severe adverse events, nausea, urinary tract infection, back pain, thoracic pain, muscle contracture, myalgia, headache
  NCT00816803 \[[@b41-inj-2040150-075]\]   Phase1/2               Chromic SCI with thoracic spinal trauma           70                10--36            Autologous BM-MSCs with physiotherapy (n = 50), standard rehabilitative therapy with physiotherapy (n = 20)   Intrathecal injection                                                                   Autologous BM-MSCs with physiotherapy group: 17 patients showed improvement of the ASIA score, 23 patients showed improvement of motor function                                                       Headaches, mild pain
  NCT01274975 \[[@b42-inj-2040150-075]\]   Phase 1                Traumatic SCI (ASIA grade A or B)                 8                 19--60            Autologous ADSCs                                                                                              Intravenous infusion                                                                    MRI at 12 weeks after therapy showed a reduction of injured lesions without significance. Conversion from ASIA A to ASIA C and improvement of motor and sensory function were noted in 1 patient      No severe adverse events
  NCT01393977 \[[@b43-inj-2040150-075]\]   Phase 3                Thoracolumbar SCI                                 34                20--50            UC-MSC transplantation group, rehabilitation therapy group, control group                                     Intrathecal injection                                                                   Seven of 10 patients treated with UC-MSCs showed significant improvement of motor function                                                                                                            Radiating neuralgia after UC-MSC transplantation; improvement within 24 hours

SCI, spinal cord injury; ASIA, American Spinal Injury Association; BM-MSCs, bone marrow stem cells; AIS, Association Impairment Scale; SSEP, somatosensory evoked potential; ADSCs, adipose-derived mesenchymal stem cells; MRI, magnetic resonance imaging; UC-MSCs, umbilical cord mesenchymal stem cells.

###### 

Clinical trials including evaluations of neurogenic bladder (<http://clinicaltrials.gov/>)

  Identifier         Clinical trial phase                     Type of SCI   No. of patients                                   Age (yr), range   Cell type   Delivery method                                                              Efficacy                                                                                UDS                                                                                                                                                                                                   Safety                                                                                                                                                                                                        
  ------------------ ---------------------------------------- ------------- ------------------------------------------------- ----------------- ----------- ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Completed trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                     NCT02152657                              Phase 1       Chronic SCI (ASIA grade A)                        5                 18--65      Autologous BM-MSCs                                                           Percutaneous administration                                                             NR                                                                                                                                                                                                    NR                                                                                                                                                                                                            NR
                     NCT01325103 \[[@b39-inj-2040150-075]\]   Phase 1       Thoracic or lumbar traumatic SCI (ASIA grade A)   14                18--65      Autologous BM-MSCs                                                           Intralesional injection after laminectomy and decompression of the spinal lesion area   Variably enhanced sensitivity below the injury area was observed. 9 patients: improvement of lower limb motor function, 7 patients: improvement of AIS, 3 patients: improvement of neuropathic pain   Increased maximum cystometric capacity without significance, significant improvement of compliance, improvement of bladder sensation. Urinary incontinence was not improved. CIC was needed after treatment   14 patients: discharge within 48 hours after surgery, 1: cerebrospinal leak related to surgery, No severe adverse events
                     NCT01909154                              Phase 1       Chronic paraplegia (ASIA grade A)                 9                 18--50      Autologous BM-MSCs                                                           Intrathecal injection (second injection at 3 months after the first injection)          Sensory recovery, improvement of chronic pain, presence of SSEPs                                                                                                                                      Increased bladder compliance, decreased detrusor pressure                                                                                                                                                     No severe adverse events, nausea, urinary tract infection, back pain, thoracic pain, muscle contracture, myalgia, headache
                     NCT02570932                              Phase 2       Chronic SCI                                       10                18--70      Autologous BM-MSCs                                                           Intrathecal injection                                                                   NR                                                                                                                                                                                                    NR^[a)](#tfn1-inj-2040150-075){ref-type="table-fn"}^                                                                                                                                                          NR
                     NCT01393977 \[[@b43-inj-2040150-075]\]   Phase 3       Thoracolumbar SCI                                 34                20--50      UC-MSCs transplantation group, rehabilitation therapy group, control group   Intrathecal injection                                                                   Seven of 10 patients treated with UC-MSCs showed significant improvement of motor function.                                                                                                           Significantly increased maximum bladder capacity, significantly decreased detrusor pressure, increased maximum flow rate without significance                                                                 Radiating neuralgia after UC-MSC transplantation; improvement within 24 hours
  Ongoing trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                     NCT03521336                              Phase 2       Subacute SCI                                      84                18--65      BM-MSCs                                                                      Intrathecal injection                                                                   NR                                                                                                                                                                                                    NR                                                                                                                                                                                                            NR
                     NCT03521323                              Phase 2       Early-stage of chronic SCI                        66                ≥ 18        BM-MSCs                                                                      Intrathecal injection                                                                   NR                                                                                                                                                                                                    NR                                                                                                                                                                                                            NR
                     NCT03003364                              Phase 1/2     Chronic SCI                                       10                18--65      WJ-MSC                                                                       Intrathecal injection                                                                   NR                                                                                                                                                                                                    NR                                                                                                                                                                                                            NR
                     NCT02687672                              Phase 2       Chronic complete SCI                              50                5--50       Autologous BM-MSCs                                                           NR                                                                                      NR                                                                                                                                                                                                    NR                                                                                                                                                                                                            NR
                     NCT01772810                              Phase 1       Chronic SCI                                       8                 18--65      Human-spinal cord-derived neural stem cell                                   NR                                                                                      NR                                                                                                                                                                                                    NR                                                                                                                                                                                                            NR

SCI, spinal cord injury; UDS, urodynamic study; ASIA, American Spinal Injury Association; BM-MSCs, bone marrow stem cells; AIS, Association Impairment Scale; SSEP, somatosensory evoked potential; ADSCs, adipose-derived mesenchymal stem cells; BM-MSCs, umbilical cord mesenchymal stem cells; CIC, clean intermittent catheterization; WJ-MSCs, Wharton's jelly mesenchymal stem cells; NR, not reported.

Bladder function was evaluated with the Neurorestoratology-Spinal Cord Injury Functional Rating Scale.
